© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Scilex Holding Company (SCLXW) stock declined over -35.58%, trading at $0.12 on NASDAQ, down from the previous close of $0.19. The stock opened at $0.17, fluctuating between $0.12 and $0.17 in the recent session.
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid therapies for patients with acute and chronic pain. The company's principal product includes ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102 or SEMDEXA, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase 3 clinical trial to treat lumbosacral radicular pain; SP-103 for the treatment of low back pain, which is in Phase 2 clinical trails; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia that is in Phase 1 clinical trials. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.
| Employees | 115 |
| Beta | 1.34 |
| Sales or Revenue | $46.74M |
| 5Y Sales Change% | 1.407% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |